SURAMIN ATTENUATES DYSTROPHIN-DEFICIENT CARDIOMYOPATHY IN THE mdx MOUSE MODEL OF DUCHENNE MUSCULAR DYSTROPHY

Author(s)

Moreira, Drielen De Oliveira ^[1] ; Pereira, Juliano Alves ^[1] ; Tiemi Taniguti, Ana Paula ^[1] ; Matsumura, Cintia Yuri ^[1] ; Ferreira Ramos, Luis Alberto ^[1] ; Areas, Miguel Arcanjo ^[1] ; Neto, Humberto Santo ^[1] ; Marques, Maria Julia ^[1]

Affiliation

^[1] Univ Estadual Campinas UNICAMP, Inst Biol, Dept Biol Estrutural & Func, BR-13083970 Campinas, SP - Brazil

• Document type: Journal article
• Source: MUSCLE & NERVE; v. 48, n. 6, p. 911-919, DEC 2013.
• Web of Science Citations: 4

Abstract

Introduction: The purpose of this study was to determine the effects of suramin, an antifibrotic agent, on cardiac function and remodeling in mdx mice. Methods: mdx mice (8 months old) received intraperitoneal injections of suramin twice a week for 3 months. Control mdx mice (8 months old) were injected with saline. Results: Suramin improved the electrocardiography profile with the main corrections seen in S- to R-wave ratio, PR interval, and Q amplitude, and a significant decrease in the cardiomyopathy index. Suramin decreased myocardial fibrosis, inflammation, and myonecrosis. Conclusions: These findings suggest that suramin may be a new adjunctive therapy to help improve cardiomyopathy in DMD. Muscle Nerve48: 911-919, 2013 (AU)

• FAPESP's process: 12/03498-7 - Mechanistic insights on the effects of suramin, on the cardiomyopathy of the mdx mice.
• Grantee: Drielen de Oliveira Moreira
• Support Opportunities: Scholarships in Brazil - Doctorate